EUVIMEDEUVIMED entdecken
Crossref

miRNA-767 and its binding site polymorphism in the mTOR gene act as potential biomarkers for female reproductive cancers

Rabia Shafique, Ishrat Mahjabeen iD, Kashaf Bibi, Farah Kalsoom, Muhammad Rizwan iD, Nida Sarosh Ashraf iD, Azhar Mehmood, Maria Fazal Ul Haq, Sumaira Fida Abbasi, Nadia Saeed, Mahmood Akhtar Kayani iD

Future Oncology · 2023

DOI: 10.2217/fon-2022-1055 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Future Oncology, 2023. Verfasst von Rabia Shafique und 10 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Genetics & Epigenetics Research Group, Department of Biosciences, COMSATS University, Park Road Islamabad, Pakistan. Hauptthemen laut MEDLINE: Breast Neoplasms, MicroRNAs, Uterine Cervical Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

The present study aimed to understand the relationship between the mTOR gene SNP (rs2536) and reproductive cancer risk. The expression level of miRNA-767 was also assessed.

Methods

700 tumor samples (300 breast, 200 ovarian and 200 cervical cancers), along with adjacent uninvolved control tissue, were used. rs2536 was screened using Tetra-ARMS PCR and expression level of miRNA-767 was assessed using quantitative PCR.

Results

The frequency of the homozygous mutant genotype of rs2536 was observed significantly higher in breast (p < 0.04), ovarian (p < 0.005) and cervical (p < 0.003) cancers. Significant downregulation of miRNA-767 was observed in tumors compared with controls.

Conclusion

The present study demonstrates that increased mutant frequency of rs2536 and deregulation of miRNA-767 are associated with increased reproductive cancer risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsMicroRNAsUterine Cervical NeoplasmsFemaleHumansBinding SitesBiomarkersBiomarkers, TumorCase-Control StudiesGenetic Predisposition to DiseasePolymorphism, Single NucleotideTOR Serine-Threonine Kinases

Stichwörter der Autor:innen

SNPbreast cancercervical cancermTORovarian cancerreproductive cancersrs2536

Substanzen

BiomarkersBiomarkers, TumorMicroRNAsMIRN-767 microRNA, humanTOR Serine-Threonine KinasesMTOR protein, human

Autor:innen und Institutionen

  • Cancer Genetics & Epigenetics Research Group, Department of Biosciences, COMSATS University, Park Road Islamabad, Pakistan.
  • Department of Pathology, Sir Ganga Ram Hospital, Lahore, Pakistan.

ORCID-Profile: Ishrat Mahjabeen, Muhammad Rizwan, Nida Sarosh Ashraf, Mahmood Akhtar Kayani

Zitieren

APA

Shafique, R., Mahjabeen, I., Bibi, K., Kalsoom, F., Rizwan, M., Ashraf, N. S., Mehmood, A., Ul Haq, M. F., Abbasi, S. F., Saeed, N., & Kayani, M. A. (2023). miRNA-767 and its binding site polymorphism in the mTOR gene act as potential biomarkers for female reproductive cancers. Future Oncology. https://doi.org/10.2217/fon-2022-1055

Vancouver

Shafique R, Mahjabeen I, Bibi K, Kalsoom F, Rizwan M, Ashraf NS, et al. miRNA-767 and its binding site polymorphism in the mTOR gene act as potential biomarkers for female reproductive cancers. Future Oncology. 2023. doi:10.2217/fon-2022-1055

BibTeX
@article{Shafique2023,
  author = {Shafique, Rabia and Mahjabeen, Ishrat and Bibi, Kashaf and Kalsoom, Farah and Rizwan, Muhammad and Ashraf, Nida Sarosh and Mehmood, Azhar and Ul Haq, Maria Fazal and Abbasi, Sumaira Fida and Saeed, Nadia and Kayani, Mahmood Akhtar},
  title = {miRNA-767 and its binding site polymorphism in the mTOR gene act as potential biomarkers for female reproductive cancers},
  journal = {Future Oncology},
  year = {2023},
  doi = {10.2217/fon-2022-1055}
}
Kostenlos starten →